ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Cohort Study"

  • Abstract Number: 1924 • ACR Convergence 2022

    Reading the Waves: Identifying Distinct Phenotypes of Multisystem Inflammatory Syndrome in Children During the 2020-2021 COVID-19 Pandemic

    Thomas Renson1, Nils Forkert1, Kimberly Amador1, Paivi Miettunen1, Simon Parsons1, Muhammed Dhalla1, Nicole Johnson2, Nadia Luca2, Heinrike Schmeling1, Rebeka Stevenson1, Marinka Twilt1, Lorraine Hamiwka1 and Susanne Benseler1, 1Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 2University of Calgary, Calgary, AB, Canada

    Background/Purpose: The COVID-19-associated multisystem inflammatory syndrome in children (MIS-C) is characterized by Kawasaki disease (KD)-like mucocutaneous features. The clinical course is often unpredictable. The goals…
  • Abstract Number: 2216 • ACR Convergence 2022

    JAK Inhibitors and Risk of Cancer

    Amandine Gouverneur1, Jérôme Avouac2, Clément Prati3, Jean-Luc Cracowski4, Thierry schaeverbeke5, Antoine Pariente1 and Marie-Elise Truchetet5, 1Université de Bordeaux, Bordeaux, France, 2University of Paris, Paris, France, 3Service de rhumatologie, CHU de Besançon, Besançon, France, 4Université de Grenoble, Grenoble, France, 5CHU de Bordeaux, Bordeaux, France

    Background/Purpose: Recent concerns have been raised about potential increase of cancer risk under JAK inhibitors (JAKi) especially tofacitinib. Discrepant findings have been given by randomized…
  • Abstract Number: 0125 • ACR Convergence 2022

    Baseline Characteristics in Patients with Eosinophilic Granulomatosis with Polyangiitis in the U.S. Initiating Mepolizumab

    Jared Silver1, Arijita Deb2, Elizabeth Packnett3, Donna McMorrow3, Cynthia Morrow3 and Michael Bogart1, 1GlaxoSmithKline, Research Triangle Park, NC, 2GlaxoSmithKline, Upper Providence, PA, 3IBM Watson Health, Cambridge, MA

    Background/Purpose: EGPA is a multisystem disorder often characterized clinically by asthma, chronic rhinosinusitis, and prominent eosinophilia, and histopathologically by eosinophil-rich, necrotizing , granulomatous vasculitis of…
  • Abstract Number: 0719 • ACR Convergence 2022

    Effect of Patient-reported Outcomes on Changes in DMARD Therapy Among Rheumatoid Arthritis Patients Treated in Routine Clinical Practice

    Lauren Stevens1, Kyra Mulder2, Zhaohui Su2, Pam Kumparatana2, Jessica Paulus2 and Stefan Weiss3, 1OM1, Inc., Lexington, KY, 2OM1, Inc., Boston, MA, 3OM1, Inc., Chapel Hill, NC

    Background/Purpose: Patient-reported outcomes (PROs) are being increasingly utilized in clinical trials to assess the impact of treatment on symptom control and patient quality of life.…
  • Abstract Number: 1186 • ACR Convergence 2022

    The Trajectory of Multimorbidity in Patients with Systemic Lupus Erythematosus in the United States

    Ali Duarte-Garcia1, Maria Stevens2, Herbert Heien2, Gabriel Figueroa Parra1, Jose A Meade-Aguilar1, Molly M. Jeffery2, Uma Thanarajasingam1, Cynthia Crowson3 and Rozalina McCoy2, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Rochester, 3Mayo Clinic, Eyota, MN

    Background/Purpose: The presence of multiple chronic conditions (multimorbidity) is associated with disability and premature death. We determined the trajectory of multimorbidity in SLE compared to…
  • Abstract Number: 1591 • ACR Convergence 2022

    Overall and Post-vaccination Prevalence of Severe COVID-19-related Events Among Commercially Insured Patients with Systemic Lupus Erythematosus and the General U.S. Population

    Sandra Sze-jung Wu1, Gelareh Atefi2, Meghan Moynihan3, Kristin Evans3, Liisa Palmer3, Michael Pollack2, Christine Dube4 and Cassandra Calabrese5, 1AstraZeneca, Hockessin, DE, 2AstraZeneca, Wilmington, DE, 3Merative, Cambridge, MA, 4AstraZeneca, Torrington, CT, 5Cleveland Clinic Foundation, Cleveland Heights, OH

    Background/Purpose: To assess the prevalence of severe COVID-19 (COVID) overall and following vaccination among patients with systemic lupus erythematosus (SLE) and the general population, and…
  • Abstract Number: 1957 • ACR Convergence 2022

    Detangling Heterogeneity in Contemporary Undifferentiated Arthritis – a Large Cohort Study Using Latent Class Analysis

    Nikolet den Hollander1, Marloes Verstappen2, Bastiaan van Dijk3, Annette van der Helm-van Mil4 and Hanna van Steenbergen3, 1Leids Universitair Medisch Centrum, Leiden, Netherlands, 2Leiden University Medical Center, Leiden, Netherlands, 3Leiden University Medical Centre (LUMC), Leiden, Netherlands, 4Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands

    Background/Purpose: Undifferentiated arthritis (UA) is considered to be heterogenous and consists of subgroups, this notion is affirmed by differences in disease course, varying from spontaneous…
  • Abstract Number: 2225 • ACR Convergence 2022

    Physical Inactivity Is Associated with Increased Expression of T Cell Inflammatory Genes in Systemic Lupus

    Sarah Patterson1, Sebastian Cruz Gonzalez2, Alexandra Tsitsiklis2, Cristina Lanata3, Lenka Maliskova4, Chun Ye1, Zachary Cutts4, Jinoos Yazdany5, Maria Dall'Era6, Lindsey Criswell7, Charles Langelier2, Patricia Katz5 and Marina Sirota8, 1University of California, San Francisco, San Francisco, CA, 2UCSF, San Francisco, CA, 3NIH, Washington, DC, 4University of California, San Francisco, San Francisco, 5UCSF, San Rafael, CA, 6University of California, Division of Rheumatology, San Francisco, CA, 7National Human Genome Research Institute, NIH, Bethesda, MD, 8UCSF, SF

    Background/Purpose: Prior studies show an independent association between greater physical activity and lower inflammatory markers among adults in the general population, but the impact of…
  • Abstract Number: 0131 • ACR Convergence 2022

    Racial Differences in Bone Health of Sarcoidosis Patients: A Retrospective Study

    Emily Peninger1, Christian Ascoli2, Rachel Lane2, Subash Kukreja2, Robert Baughman3 and Nadera Sweiss2, 1University of Chicago, Chicago, IL, 2University of Illinois at Chicago, Chicago, IL, 3University of Cincinnati, Cincinnati, OH

    Background/Purpose: Bone health in sarcoidosis is a complex topic, though data regarding racial differences in this population is lacking. Our study sought to identify racial…
  • Abstract Number: 0720 • ACR Convergence 2022

    Risk-Benefit Assessment of Primary Prophylaxis for Pneumocystis Pneumonia in Patents with Rheumatic Diseases Exposed to Rituximab: A Multicenter Cohort Study

    Jun Won Park1, Jeffrey Curtis2, Min Jung Kim3, You-Jung Ha4, Yun Jong Lee4 and Eun Bong Lee1, 1Seoul National University Hospital, Seoul, Republic of Korea, 2Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 3Seoul Metropolitan Government Boramae Medical center, Dongjak-gu, Seoul, Republic of Korea, 4Seoul National University Bundang Hospital, Seongnam, Republic of Korea

    Background/Purpose: Although previous studies suggested that primary prophylaxis for pneumocystis pneumonia (PJP) during rituximab treatment could be beneficial, it is uncertain whether this strategy should…
  • Abstract Number: 1195 • ACR Convergence 2022

    Duloxetine and the Risk for Acute Myocardial Infarction and Stroke in Medicare Recipients with Non-Cancer Pain

    Meghan Corriere, Alyson Dickson, Laura Daniel, Puran Nepal, Kathi Hall, Dale Plummer, William Dupont, Katherine Murray, Michael Stein, Wayne Ray and Cecilia Chung, Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Duloxetine is a serotonin-norepinephrine reuptake inhibitor antidepressant also prescribed for musculoskeletal and other forms of chronic pain. Its dual pharmacologic properties have the potential…
  • Abstract Number: 1594 • ACR Convergence 2022

    Incidence of Pneumocystis Jirovecii Pneumonia and Prophylaxis-Associated Adverse Events Among Patients with Systemic Lupus Erythematosus

    Yiran Jiang1, Ali Duarte-Garcia2, Mike Putman3 and David Gazeley4, 1Medical College of Wisconsin, Milwaukee, WI, 2Mayo Clinic, Rochester, MN, 3The Medical College of Wisconsin, Milwaukee, WI, 4Medical College of Wisconsin, Wauwatosa, WI

    Background/Purpose: Pneumocystis jirovecii Pneumonia (PJP) is an opportunistic infection that may affect patients receiving immunosuppression. There are no consensus guidelines for PJP prophylaxis among patients…
  • Abstract Number: 1961 • ACR Convergence 2022

    COVID-19 mRNA Vaccine Induced Antibody Titers and IFN-g Responses Are Decreased in Persons with Rheumatoid Arthritis and Older Age

    Holly Dudley1, megan O'Mara2, Ann Auma1, Jenny Gong3, Yael Ross4, Natalie Gurevich2, Larraine Gordesky5, Nora Singer6, Lenche Kostadinova7, Brigid Wilson7, David Zidar7, Christopher King1, David Canaday1, Carey Shive1, Maya Mattar8 and Donald Anthony9, 1Case Western Reserve University, Cleveland, OH, 2Cleveland Veteran Affairs Medical Center, Cleveland, OH, 3Case Western School of Medicine, Cleveland, OH, 4Case Western Reserve University at MetroHealth Medical Center, Atlanta, GA, 5MetroHealth Medical Center, Cleveland, OH, 6The MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH, 7VA Medical Center, Cleveland, OH, 8Louis Stokes VA Medical Center, Mayfield Heights, OH, 9Case, VA, Metro, Chardon, OH

    Background/Purpose: People with autoimmune diseases have worse outcomes if infected by SARS-CoV2. In particular, persons with rheumatoid arthritis (RA), have lower antibody responses to COVID-19…
  • Abstract Number: 2232 • ACR Convergence 2022

    Clinical Features and Long-term Outcomes of Patients with Systemic Polyarteritis Nodosa Diagnosed Since 2005: Data from 196 Patients

    Julien ROHMER1, ludovic trefond2, Yann Nguyen3, Christian Agard4, Jean Sebastien ALLAIN5, Alice Berezne6, Pierre Charles7, Pascal Cohen8, guillaume gondran9, Matthieu GROH10, Tessa HUSCENOT11, carole lacout12, Estibaliz Lazaro13, Jonathan London14, Francois Maurier15, Arsene Mekinian16, Isabelle Nubourgh17, Rafik MESBAH18, Xavier Puéchal8, Laurent Perard19, Mathieu Puyade20, Gregory Pugnet21, Viviane Queyrel22, Diane Rouzaud23, Arthur Roux24, Cecile-Audrey DUREL19, Loïc Guillevin8 and Benjamin Terrier8, 1APHP, Suresnes, France, 2Chu clermont ferrand, Clermont-Ferrand, France, 3AP-HP.Centre Universit Paris Cit Hôpital Cochin, Montmorency, France, 4Internal medicine, Nantes University Hospital, Nantes, France, 5CHU rennes, Rennes, 6CH Annecy, Annecy, France, 7Institut Mutualiste Montsouris, Service de Médecine Interne, Paris, France, 8National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, 9CHU limoges, Limoges, France, 10Foch Hospital, Suresnes, France, 11APHP, Boulogne, France, 12CHU Angers, Angers, France, 13Bordeaux Hospital University, Bordeaux, France, 14Hôpital Croix-Saint-Simon, Paris, France, 15Hôpitaux privés de Metz, Metz, France, 16AP-HP, Hopital Saint Antoine, Paris, France, 17Ch St Pierre, Brussels, Belgium, 18Boulogne Ch, Boulogne, France, 19CHU Lyon, Lyon, France, 20Centre Hospitalier Universitaire de Poitiers, Poitiers, France, 21CHU Toulouse Purpan Service de Medecine Interne, Toulouse, France, 22CHU NIce, Nice, France, 23Bichat, Paris, France, 24MGEN, Paris, France

    Background/Purpose: The etiological landscape of systemic polyarteritis nodosa (PAN) has substantially changed since the onset of hepatitis B virus (HBV) vaccination and the discovery of…
  • Abstract Number: 0136 • ACR Convergence 2022

    Sarcoidosis Incidence After mTOR Inhibitor Treatment

    Matthew Baker1, Emese Vágó2, Yuhan Liu1, Rong Lu1, Suzanne Tamang3, Erzsébet Horváth-Puhó2 and Henrik Sørensen2, 1Stanford University, Stanford, CA, 2Aarhus University Hospital, Aarhus, Denmark, 3Stanford Center for Population Health Sciences, Redwood City, CA

    Background/Purpose: Mechanistic target of rapamycin (mTOR) inhibitors are effective in animal models of granulomatous disease, but their benefit in patients with sarcoidosis is unknown. We…
  • « Previous Page
  • 1
  • …
  • 13
  • 14
  • 15
  • 16
  • 17
  • …
  • 28
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology